hOw@rdgrop

Key Highlights Group Two clinical study underway - Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026. Moving beyond safety - The Group Two study will evaluate the Ocumetics Lens for safety plus near-and distance-vision performance. Next-generation technology - Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system. 12-month data milestone approaching - Group One patients are

Calgary, Alberta – TheNewswire - August 24, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “Offering”).   The Corporation

Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire - May 12, 2026

Calgary, Alberta – TheNewswire - April 29, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to

Key Highlights   Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements Safety profile: Continues to meet expectations Quality-of-life improvements: Anecdotally, all patients reported life changing results from lens implantations Technology validation: Results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens Momentum: Forward momentum continues, with lens design enhancements

Key Highlights   No material change: There is no material change in the business affairs of Ocumetics. Attendance at ASCRS: Productive ASCRS meetings with major global ophthalmic leaders. Clinical and development momentum: Feedback supported positive results from the First-in-Human (FIH) Group 1 study while the Company advances toward Group 2 patient recruitment and upcoming surgeries. Regulatory

Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire - April 1, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:

Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full

Calgary, Alberta – February 10, 2026 – TheNewswire - Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release

Key Highlights   Positive First-in-Human Results: Three-month Group 1 data met or exceeded expectations for safety, lens delivery, and vision performance.   Major De-Risking Milestone: The study successfully validated the core technology and cleared the path to the next clinical phase. Life-Changing Vision Improvements: Patients with severe vision loss experienced meaningful improvements in everyday